Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 2196 • 2015 ACR/ARHP Annual Meeting
Association Between Antiphospholipid Antibodies and All-Cause Mortality Among End Stage Renal Disease Patients with and without SLE
Anna R. Broder¹, Wenzhu Mowrey², Mimi Kim³, Irina Murakhovskaya⁴, Joel Neugarten⁵, Karen H. Costenbader⁶ and Chaim Putterman⁷, ¹Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Department of Epidemiology and Population Health/Division of Biostatistics, Albert Einstein College of Medicine, Bronx, NY, ³Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁴Medicine/Hametology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁵Medicine/Nephrology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁶Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: We investigated the association between the presence of antiphospholipid antibodies (aPL) and/or lupus anticoagulant (LAC) (aPL/LAC+) and all-cause mortality among end stage renal…
Abstract Number: 2197 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in First-Line Treated Pregnancies in Antiphospholip Antibodies-Positive Women According to Different Treatment Protocols: A Single Center Experience over 30 Years
Maria Grazia Lazzaroni¹, Laura Andreoli¹, Fabrizio Lupoli¹, Elena Aggogeri¹, Elisa Bettiga², Sonia Zatti², Andrea Lojacono², Francesca Ramazzotto², Micaela Fredi³, Cecilia Nalli⁴, Rossella Reggia¹, Francesca Dall'Ara¹, Mara Taraborelli³, Roberto Gorla³, Matteo Filippini³, Marco Taglietti³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy
Background/Purpose: Antiphospholipid antibodies (aPL) are risk factors for Adverse Pregnancy Outcome (APO). Risk stratification may include several demographic, clinical and serological variables. Still debated is…
Abstract Number: 2200 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients
Stephane Zuily¹, Cecilia B. Chighizola², DENIS WAHL¹, Pier Luigi Meroni³ and Doruk Erkan⁴, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, ²Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Cusano Milanino, Italy, ³University of Milan, Department of Clinical Sciences and Community Health, Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, ⁴Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of persistently antiphospholipid antibodies (aPL)-positive patients ± autoimmune disorders over…
Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Cécile Yelnik^1,2, Elodie Drumez³, Sylvain Dubucquoi^2,4,5, Vincent Sobanski^1,2,4, Hélène Maillard^1,6, Alain Duhamel³, David Launay^1,2,4, Eric Hachulla^1,2,4, Pierre-Yves Hatron^1,2 and Marc Lambert^1,2,4, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³CERIM, Université Lille Nord de France, Lille, France, ⁴LIRIC, INSERM UMR 995, Lille, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…
Abstract Number: 1752 • 2015 ACR/ARHP Annual Meeting
Characterization of Epitopes Identified with Cerebral Vasculature Injury
Melissa Butts¹, Jess Edison¹, Christopher Tracy¹, Brian Stout¹, Huazhen Chen² and Chantal Moratz², ¹Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Medicine, Uniformed Services University School of Health Sciences, Bethesda, MD
Background/Purpose: There is an association between natural antibodies, such as anti-phospholipid antibodies, and vasculature injury in stroke and in SLE models of systemic ischemic damage. …
Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Jane E. Salmon^1,2, Mimi Kim³, Marta Guerra⁴, Elianna Kaplowitz¹, Carl Laskin⁵, Michelle Petri⁶, Ware D. Branch^7,8, Michael Lockshin⁹, Lisa R. Sammaritano², Joan T. Merrill¹⁰, Mary D. Stephenson¹¹, Munther Khamashta¹², Alan M. Peaceman¹³, Anne Lynch¹⁴ and Jill P. Buyon¹⁵, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁴Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁵Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹University of Illinois College of Medicine, Chicago, IL, ¹²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ¹³Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁴Colorado School of Public Health, Aurora, CO, ¹⁵NYU School of Medicine, New York, NY
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…
Abstract Number: 2866 • 2014 ACR/ARHP Annual Meeting
External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß₂-Glycoprotein I. a Prospective Multicentre Cohort Study
Stephane Zuily¹, Bas De Laat², Veronique Regnault³, Pierre Kaminsky⁴, Hilde Kelchtermans⁵, Zakera Shums⁶, Roger Albesa⁷, Gary L Norman⁶, Philip de Groot⁸, Anne-Christine Rat⁹, Jacques Ninet¹⁰, Nadine Magy-Bertrand¹¹, Jean-Louis Pasquali¹², Marc Lambert¹³, Bernard Lorcerie¹⁴, Thomas Lecompte¹⁵, Francis Guillemin¹⁶ and Denis Wahl¹⁷, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²Biochemistry, CARIM, Maastricht University, Maastricht, Netherlands, ³Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, ⁴Internal Medicine, CHU Nancy, Vandoeuvre, France, ⁵Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶INOVA Diagnostics, San Diego, CA, ⁷Research, INOVA Diagnostics, San Diego, CA, ⁸Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, ⁹University Paris Descartes, EA 4360 APEMAC, University of Lorraine, Nancy, France, ¹⁰Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹¹Bensançon University Hospital, Besançon, France, ¹²Service de Medecine Interne, Nouvel Hospital Civil, Strasbourg Cedex, France, ¹³Lille University Hospital, Lille, France, ¹⁴Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, ¹⁵Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹⁶INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, ¹⁷Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital and INSERM U961, Vandoeuvre-Les-Nancy, France
Background/Purpose: Our objectives were 1- to perform an external validation of the Global Anti-Phospholipid Syndrome Score (GAPSS) and 2- to compare prognostic significances of GAPPS…
Abstract Number: 2867 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps: a New Mechanism of Thrombosis in the Antiphospholipid Syndrome
Srilakshmi Yalavarthi¹, Levi F. Mazza¹, Alexandra E. Morris¹, Carlos Núñez-Álvarez², Diego Hernández², Paula L. Bockenstedt³, Antonio R. Cabral⁴ and Jason S. Knight¹, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ³Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
Background/Purpose: Antiphospholipid antibodies (aPL), especially those targeting beta-2-glycoprotein I, are known to activate endothelial cells, monocytes, and platelets, with prothrombotic implications. However, the interaction of…
Abstract Number: 2868 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Initial Analysis
Doruk Erkan¹, Danieli Andrade², Maria Tektonidou³, Amaia Ugarte⁴, Alessandra Banzato⁵, Angela Tincani⁶, Pier-Luigi Meroni⁷, Ricard Cervera⁸, Paul R. Fortin⁹, Roger A. Levy¹⁰ and On Behalf of APS Action¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Hospital Universitario Cruces, Bizkaia, Spain, ⁵Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁶Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Int Medicine, University of Milan, Milano, Italy, ⁸Hospital Clinic, Barcelona, Spain, ⁹Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ¹⁰Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹APS ACTION, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive patients…
Abstract Number: 2650 • 2014 ACR/ARHP Annual Meeting
Cognitive Impairment in SLE and Non-Criterion Anti-Phospholipid Antibodies
Michael Luggen¹, Gaurav Gulati², Rohan Willis³ and Emilio B. Gonzalez³, ¹Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Immunology, Allergy & Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ³Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: The pathogenesis of cognitive impairment (CI) in patients with SLE is unknown. Anti-phospholipid antibodies (APL) have been implicated in some studies, but not in…
Abstract Number: 2638 • 2014 ACR/ARHP Annual Meeting
The Protective Effects of Statins for Thrombosis in Patients with Systemic Lupus Erythematosus Positive for Antiphospholipid Antibodies
Toshiyuki Watanabe, Kenji Oku, Olga Amengual, Eri Sugawara, Ryo Hisada, Kazumasa Ohmura, Tomoko Fukui, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Michihito Kono, Yuka Shimizu, Takashi Kurita, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Thrombosis is one of the most frequent manifestations in patients with systemic lupus erythematosus (SLE). Although antiphospholipid antibodies (aPL) are well recognized risk factors…
Abstract Number: 1702 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance?
Anjali Shetty¹, Suncica Volkov¹, Claudia Vergara² and William Swedler³, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²Rheumatology, University of Illinois Chicago, Chicago, IL, ³Section of Rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by collagen deposition and vascular changes of the skin and internal organs, leading ultimately to fibrosis. …
Abstract Number: 1664 • 2014 ACR/ARHP Annual Meeting
Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a “sleeping beauty”?
Jorge Alcocer-Varela¹, Mariana Quintanar², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose Renal involvement in systemic lupus erythematosus (SLE) is frequent, and a high percentage of patients (~15%) develop end-stage renal disease (ESRD) even with optimal…
Abstract Number: 1342 • 2014 ACR/ARHP Annual Meeting
Improving Serologic Testing for Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus
Arshad Mustafa¹, Kara Prescott², Una Makris³ and E. Blair Solow⁴, ¹Internal Medicine - Rheumatology, UT Southwestern Medical Center at Dallas, Dallas, TX, ²Internal Med - Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ³Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ⁴Internal Medicine, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Antiphospholipid antibodies (APL) in patients with Systemic Lupus Erythematosus (SLE) are common. Persistent positivity is known to increase the risk of thrombosis and pregnancy…
Abstract Number: 691 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE)
Sergi Heredia¹, Javier Narváez², Andrea Zacarias¹, Eulalia Armengol¹, Gloria Albert¹, Alex Roset³, Patricia Siguenza³, Xavier Juanola⁴, Manel Rubio Rivas³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To determine the prevalence of unsuspected echocardiographic abnormalities (excluding pericardial effusion) and to identify associated clinical and laboratory features in a large SLE cohort.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].